The dose labels on edible medical marijuana products are mostly inaccurate. Researchers writing in the June 23–30 issue of JAMA compared the cannabinoid content listed on the labels of edible or potable medical cannabis products with the products’ actual cannabinoid content. They studied 75 products, representing 47 different brands, in three U.S. cities with dispensary menus (San Francisco, Los Angeles, and Seattle) and found that 83% of the products were inaccurately labeled: 60% were overlabeled (had lower amounts of active ingredients than claimed) and 23% were underlabeled. These results may not be generalizable, say the authors, because a comprehensive list of dispensaries isn’t available and some products aren’t labeled at all. But the results indicate that the variability in labeling accuracy in some of the largest markets for medical cannabis in the United States merits consideration.
